Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553562 | 0.88 | ALDH1A1 (0.78) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL18815387 | 0.87 | SMN1; SMN2 (1.00) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL18794993 | 0.86 | ALDH1A1 (0.76) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL1257597 | 0.86 | ALDH1A1 (0.76) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL1719412 | 0.86 | ALDH1A1 (0.75) | ALDH1A1LMNASMN1; SMN2HPGDCYP19A1 | |
| SCHEMBL18795075 | 0.85 | SMN1; SMN2 (0.78) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL15874039 | 0.84 | ALDH1A1 (0.72) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL6072158 | 0.84 | ALDH1A1 (0.73) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL25332941 | 0.84 | ALDH1A1 (0.72) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 | |
| SCHEMBL3648310 | 0.83 | ALDH1A1 (0.71) | ALDH1A1LMNASMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250563-B1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2022-01-12 | — | — | EP | disclosed |
| US-11021449-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20130045998-A1 | PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | LABORATORIOS LESVI, S.L. (ES) | 2013-02-21 | — | — | US | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045998-A1 | PROCESS FOR PREPARING RUFINAMIDE INTERMEDIATE | CYP3A5, CYP3A4, CYP4B1 | ALDH1A1 392/4885LMNA 3096/4885SMN1; SMN2 3494/4885 |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | ALDH1A1 2395/4885LMNA 1958/4885SMN1; SMN2 80/4885 |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | ALDH1A1 2404/4885LMNA 1956/4885SMN1; SMN2 81/4885 |
| US-11021449-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | ALDH1A1 259/4885LMNA 2322/4885SMN1; SMN2 20/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | ALDH1A1 2395/4885LMNA 1958/4885SMN1; SMN2 80/4885 |
| US-20170349558-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | ALDH1A1 259/4885LMNA 2322/4885SMN1; SMN2 20/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | ALDH1A1 2404/4885LMNA 1956/4885SMN1; SMN2 81/4885 |
| US-20200399229-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | ALDH1A1 259/4885LMNA 2322/4885SMN1; SMN2 20/4885 |
| US-10738017-B2 | Substituted triazoles and methods relating thereto | CYP3A43, OTC, GRIN3A | ALDH1A1 259/4885LMNA 2322/4885SMN1; SMN2 20/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | ALDH1A1 617/4885LMNA 3803/4885SMN1; SMN2 2844/4885 |
| US-20190169137-A1 | SUBSTITUTED TRIAZOLES AND METHODS RELATING THERETO | CYP3A43, OTC, GRIN3A | ALDH1A1 259/4885LMNA 2322/4885SMN1; SMN2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.